Financial Performance - Q2 2025 consolidated revenue was $95 million, reflecting an 8% QoQ rebound excluding Geomagic[29] - Medical Technologies revenue grew 13% YoY and 16% QoQ, representing over $80 million of FY'24 revenues[19] - The company achieved significant OpEx reductions of $17 million YoY and $15 million QoQ[35] - Net income for Q2 2025 was $1044 million, with GAAP EPS at $057[39] - The company expects to exit Q4'25 with operating expenses in the low $40 million range[13] Strategic Initiatives - The company completed the sale of the Geomagic business for nearly $120 million in cash on April 1, 2025[10, 44] - A debt transaction in June permanently retired $88 million in debt and refinanced $92 million through 2030, along with repurchasing 8 million common shares[10, 44] - Cost reduction and profitability improvement initiatives target over $85 million of annualized savings planned through 1H'26[12] Balance Sheet - The company ended the quarter with approximately $134 million in cash, cash equivalents, and restricted cash[44] - As of August 2025, the company's global cash, cash equivalents, and restricted cash amounted to approximately $130 million[44]